| Molecular Formula | C21H23N3O5 |
| Molar Mass | 397.42 |
| Density | 1.34 |
| Melting Point | 118-120℃ |
| Boling Point | 548.7±60.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid |
| Color | Light Yellow to Yellow |
| pKa | 7.93±0.50(Predicted) |
| Storage Condition | Refrigerator |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.516 ml | 12.581 ml | 25.162 ml |
| 5 mM | 0.503 ml | 2.516 ml | 5.032 ml |
| 10 mM | 0.252 ml | 1.258 ml | 2.516 ml |
| 5 mM | 0.05 ml | 0.252 ml | 0.503 ml |
| Overview | 3-[[3-[(dimethylamino) carbonyl]-2-hydroxyphenyl] amino]-4-[[(R)-1-(5-methylfuran-2-yl) propyl] amino] -3-cyclobutene-1, 2-Diketone is an organic chemical substance, which is an effective allosteric antagonist of CXCR1 and CXCR2, and can only be used in scientific research experiments. |
| biological activity | Navarixin (SCH-527123, MK-7123, PS-291822) is an effective CXCR2/CXCR1 antagonist with oral bioavailability, IC50 is 2.6 nM and 36 nM respectively. |
| target | TargetValue CXCR2 (Cell-free assay) 2.6 nM CXCR1 (Cell-free assay) 36 nM |
| Target | Value |
| CXCR2 (Cell-free assay) | 2.6 nM |
| CXCR1 (Cell-free assay) | 36 nM |